$ 320,000

On May 10, 2019, 4,000,000 shares of Generex common stock was transferred out of the Friends of Generex Biotechnology Investment Trust (the “Trust”) in consideration of 592,683 Series A voting preferred of Olaregen held by an existing shareholder in Olaregen. A $2,000,000 promissory note from Genrex to the existing shareholder in Olaregen remains outstanding. The 592,683 represents approximately 10% voting control of Olaregen. The $2,000,000 was extended to have a maturity date of August 1, 2019. Subsequent to this transaction, there are 2,366,187 Olaregen shares that belong to non-controlling interest shareholders which represents a 37.9% non-controlling interest.

Obligation for stock transferred

$ 1,000,000

Subsequent Events (Details Narrative) - USD ($)			1 Months Ended		9 Months Ended
Subsequent Events (Details Narrative) - USD ($)	May 22, 2019	May 10, 2019	May 22, 2019	Apr. 30, 2019	Apr. 30, 2019
Payment of Promissory Note				$ 320,000	$ 320,000
Subsequent Event [Member]
Subsequent event description		On May 10, 2019, 4,000,000 shares of Generex common stock was transferred out of the Friends of Generex Biotechnology Investment Trust (the “Trust”) in consideration of 592,683 Series A voting preferred of Olaregen held by an existing shareholder in Olaregen. A $2,000,000 promissory note from Genrex to the existing shareholder in Olaregen remains outstanding. The 592,683 represents approximately 10% voting control of Olaregen. The $2,000,000 was extended to have a maturity date of August 1, 2019. Subsequent to this transaction, there are 2,366,187 Olaregen shares that belong to non-controlling interest shareholders which represents a 37.9% non-controlling interest.
Number of stock transferred		400,000
Obligation for stock transferred		$ 1,000,000
Payment of Promissory Note	$ 4,361,500		$ 4,800,000